IN2005KO00272A - - Google Patents
Download PDFInfo
- Publication number
- IN2005KO00272A IN2005KO00272A IN272KO2005A IN2005KO00272A IN 2005KO00272 A IN2005KO00272 A IN 2005KO00272A IN 272KO2005 A IN272KO2005 A IN 272KO2005A IN 2005KO00272 A IN2005KO00272 A IN 2005KO00272A
- Authority
- IN
- India
- Prior art keywords
- carbon atoms
- halogen
- alkyl
- formula
- alkenyl
- Prior art date
Links
- 125000004432 carbon atom Chemical group C* 0.000 abstract 24
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 125000004950 trifluoroalkyl group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
Abstract
A process for the preparation of a compound of formula I, having the structure wherein R1 is alkenyl of 2-7 carbon atoms; wherein the alkenyl moiety is optionally substituted with hydroxyl, -CN, halogen, trifluoroalkyl of 1-6 carbon atoms, trifluoroalkoxy of 1-6 carbon atoms, -COR5, -CO2R5, -NO2, CONR5R6, NR5R6 or N(R5)COR6; R2 and R2a are each, independently, hydrogen, hydroxyl, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-4 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, trifluoroalkyl of 1-6 carbon atoms, or trifluoroalkoxy of 1-6 carbon atoms; wherein the alkyl, alkenyl, or alkynyl moieties are optionally substituted with hydroxyl, -CN, halogen, trifluoroalkyl of 1-6 carbon atoms, trifluoroalkoxy of 1-6 carbon atoms, -COR5, -CO2R5, -NO2, CONR5R6, NR5R6 or N(R5)COR6; R3, and R3a are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, halogen, alkoxy of 1-4 carbon atoms, trifluoroalkyl of 1-6 carbon atoms, or trifluoroalkoxy of 1-6 carbon atoms; wherein the alkyl, alkenyl, or alkynyl moieties are optionally substituted with hydroxyl, -CN, halogen, trifluoroalkyl of 1-6 carbon atoms, trifluoroalkoxy of 1-6 carbon atoms, -COR5, -CO2R5, -NO2, CONRsRe, NR5R6 or N(R5)COR6; R5, R6 are each, independently hydrogen, alkyl of 1-6 carbon atoms or aryl of 6-10 carbon atoms; X is O, S, or NR7; R7 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, -COR5, -CO2R5 or -SO2R5; or a pharmaceutically acceptable salt thereof; comprising one of the following a) reacting a compound of formula wherein R1, R2, R2a. and X are as defined above with a compound of formula wherein R3 and R3a are as defined above and Y is halogen, -OH or hydroxyalkyl of 1 to 6 carbon atoms; or b) converting a compound of formula I as defined above to a pharmaceutically acceptable salt thereof; or c) resolving an Isomeric mixture of compounds of formula I as defined above to isolate an enantiomer of a compound of formula I or a pharmaceutically acceptable salt thereof,
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33666301P | 2001-12-05 | 2001-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2005KO00272A true IN2005KO00272A (en) | 2015-08-07 |
Family
ID=23317104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN272KO2005 IN2005KO00272A (en) | 2001-12-05 | 2005-04-04 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US6794403B2 (en) |
| EP (2) | EP1982713A3 (en) |
| JP (2) | JP4689960B2 (en) |
| KR (1) | KR20050044717A (en) |
| CN (2) | CN101423500A (en) |
| AR (1) | AR037745A1 (en) |
| AU (2) | AU2002353014A1 (en) |
| BR (1) | BR0214767A (en) |
| CA (1) | CA2467517C (en) |
| CO (1) | CO5580830A2 (en) |
| EC (1) | ECSP045133A (en) |
| HU (1) | HUP0500010A2 (en) |
| IL (1) | IL162256A0 (en) |
| IN (1) | IN2005KO00272A (en) |
| MX (1) | MXPA04005306A (en) |
| NO (1) | NO20042811L (en) |
| NZ (1) | NZ560878A (en) |
| PL (1) | PL370771A1 (en) |
| RU (2) | RU2330847C2 (en) |
| SG (1) | SG165987A1 (en) |
| TW (1) | TW200304822A (en) |
| UA (1) | UA83620C2 (en) |
| WO (1) | WO2003050095A1 (en) |
| ZA (1) | ZA200405249B (en) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1448544B1 (en) | 2001-11-19 | 2007-05-16 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
| UA83620C2 (en) | 2001-12-05 | 2008-08-11 | Уайт | Substituted benzoxazoles and analogues as estrogenic agents |
| US20040002524A1 (en) * | 2002-06-24 | 2004-01-01 | Richard Chesworth | Benzimidazole compounds and their use as estrogen agonists/antagonists |
| TW200409759A (en) * | 2002-09-25 | 2004-06-16 | Wyeth Corp | Substituted 4-(indazol-3-yl)phenols |
| PT1988397E (en) | 2002-12-19 | 2011-12-02 | Scripps Research Inst | COMPOSITIONS AND UTILIZATIONS FOR TRANSTYRETIN STABILIZATION AND WIND INHIBITION |
| PT1626974E (en) | 2003-04-21 | 2008-11-14 | Lilly Co Eli | Substituted benzopyrans as selective estrogen receptor-beta agonists |
| TW200500065A (en) * | 2003-05-21 | 2005-01-01 | Wyeth Corp | Antiarthritic combinations |
| WO2005113523A1 (en) | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| US20060004087A1 (en) * | 2004-07-01 | 2006-01-05 | Wyeth | Tetracyclic compounds as estrogen ligands |
| JP2008510827A (en) * | 2004-08-26 | 2008-04-10 | ワイス | Prodrug-substituted benzoxazoles as estrogen agents |
| WO2006028875A1 (en) | 2004-09-02 | 2006-03-16 | Wyeth | Phenanthridine carbonyl phenols as cytokine modulators |
| BRPI0514974A (en) | 2004-09-07 | 2008-07-01 | Wyeth Corp | compound, composition, methods of treating or inhibiting a disease or condition, free radical-induced disease states in a mammal, damage to the joint secondary to arthroscopic or surgical procedures in a mammal, infertility in a mammal, lowering cholesterol levels, triglycerides, lp (a), or ldl, to provide cognition or neuroprotection enhancement, contraception in a mammal, and to prepare a compound, and, product |
| JP2008521921A (en) * | 2004-12-02 | 2008-06-26 | ワイス | Substituted benzoxazole formulations |
| BRPI0518786A2 (en) * | 2004-12-02 | 2008-12-09 | Wyeth Corp | pharmaceutical formulation, process for preparing a pharmaceutical formulation, product, and capsule or tablet |
| CN101111229A (en) * | 2004-12-02 | 2008-01-23 | 惠氏公司 | Formulations of substituted benzoxazoles |
| PA8656601A1 (en) * | 2004-12-17 | 2006-12-07 | Wyeth Wyeth | NEW USES FOR BETA DE ESTROGEN AGONISTS |
| EP1853578A1 (en) * | 2005-02-15 | 2007-11-14 | Eli Lilly And Company | Substituted tetralins as selective estrogen receptor-beta agonists |
| AR053332A1 (en) * | 2005-02-16 | 2007-05-02 | Wyeth Corp | USE OF SELECTIVE AGONISTS FOR THE STROGEN BETA RECEIVER (ERP) FOR MUCOSITIS INDICATED BY RADIATION OR BY CHEMOTHERAPY AND FOR RADIATION INDUCED CYSTITIS |
| JP2008531748A (en) * | 2005-03-07 | 2008-08-14 | ワイス | Purification process for substituted benzoxazole compounds |
| CN101137627A (en) * | 2005-03-07 | 2008-03-05 | 惠氏公司 | Process for the preparation of substituted benzoxazole compounds |
| JP2008533012A (en) * | 2005-03-08 | 2008-08-21 | ワイス | Crystal formation of 2- (3-fluoro-4-hydroxyphenyl) -7-vinyl-1,3-benzoxazol-5-ol and its use as an estrogen receptor modulator |
| BRPI0610308A8 (en) | 2005-05-26 | 2017-04-25 | Neuron Systems Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DISEASE |
| PE20070427A1 (en) | 2005-08-30 | 2007-04-21 | Novartis Ag | BENZIMIDAZOLES DERIVED COMPOUNDS SUBSTITUTED AS TYROSINE KINASE INHIBITORS |
| AR059574A1 (en) * | 2006-02-14 | 2008-04-16 | Wyeth Corp | PHARMACEUTICAL FORMULATIONS WATERPROOF SELECTIVE LIGANDS ER-BETA |
| AR059741A1 (en) * | 2006-03-06 | 2008-04-23 | Wyeth Corp | LIQUID AND SEMISOLID PHARMACEUTICAL FORMULATIONS AND PROCEDURES |
| AR059742A1 (en) * | 2006-03-06 | 2008-04-23 | Wyeth Corp | PHARMACEUTICAL FORMULATIONS OF AN ANHYDRA CRYSTAL FORM OF 2- (3- FLUOR-4- DIHYDROXIFENIL) 7- VINIL-1,3- BENZOXAZOL -5-OL |
| US20070208067A1 (en) * | 2006-03-06 | 2007-09-06 | Wyeth | Tablet Formulations and Processes |
| AR059743A1 (en) * | 2006-03-06 | 2008-04-23 | Wyeth Corp | PHARMACEUTICAL FORMULATIONS OF A CRYSTALLINE FORM OF MONOHIDRATE OF 2- (3- FLUOR-4- HYDROXYPHENYL) -7- VINIL-1,3- BENZOAXOL-5-OL |
| JP4986485B2 (en) | 2006-03-28 | 2012-07-25 | 株式会社Ａｄｅｋａ | Epoxy resin curable composition |
| WO2008034016A2 (en) * | 2006-09-15 | 2008-03-20 | Foldrx Pharmaceuticals, Inc. | Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins |
| US20080241234A1 (en) * | 2006-11-21 | 2008-10-02 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080139633A1 (en) * | 2006-11-21 | 2008-06-12 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080175901A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080146630A1 (en) * | 2006-11-21 | 2008-06-19 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| EP2064195A2 (en) * | 2006-11-21 | 2009-06-03 | Wyeth | Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and pharmaceutical formulations thereof |
| US20080176914A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20090239920A1 (en) * | 2006-11-21 | 2009-09-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080132554A1 (en) * | 2006-11-21 | 2008-06-05 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080175900A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| BRPI0806371A2 (en) | 2007-01-22 | 2011-09-13 | Gtx Inc | nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| CN101600421A (en) * | 2007-01-31 | 2009-12-09 | 惠氏公司 | Use of an estrogen receptor beta selective ligand for the treatment of acute lung injury |
| WO2008100769A2 (en) * | 2007-02-09 | 2008-08-21 | Wyeth | Process for selective sulfation of aromatic hydroxyl groups |
| US20080262009A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as acetate salts |
| US20080262010A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as d-glucoronate salts |
| US20080262008A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as succinate salts |
| US20080275073A1 (en) * | 2007-04-20 | 2008-11-06 | Wyeth | Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as pharmaceutically acceptable salts |
| WO2009009417A2 (en) * | 2007-07-06 | 2009-01-15 | Wyeth | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion |
| WO2009100335A1 (en) * | 2008-02-08 | 2009-08-13 | Wyeth | Phosphate derivatives of substituted benzoxazoles |
| WO2010036908A1 (en) * | 2008-09-26 | 2010-04-01 | Eisai R & D Management Co., Ltd. | Use of benzoxazole compounds in the treatment of malaria |
| WO2010036905A1 (en) * | 2008-09-26 | 2010-04-01 | Eisai R & D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| WO2010083199A1 (en) | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
| WO2011014516A1 (en) * | 2009-07-28 | 2011-02-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Estrogen antagonists as treatments for sclerosing disorders |
| US9814701B2 (en) | 2009-12-11 | 2017-11-14 | Aldeyra Therapeutics, Inc. | Compositions and methods for the treatment of macular degeneration |
| EP2621492A1 (en) * | 2010-10-01 | 2013-08-07 | Indiana University Research and Technology Corporation | Treatment of symptoms associated with menopause |
| WO2012118935A1 (en) * | 2011-03-03 | 2012-09-07 | Proteotech Inc | Compounds for the treatment of neurodegenerative diseases |
| JP5869677B2 (en) | 2011-09-16 | 2016-02-24 | ファイザー・インク | Solid form of transthyretin dissociation inhibitor |
| BR112015015218B1 (en) * | 2012-12-27 | 2020-12-01 | Sumitomo Chemical Company, Limited | fused oxazole compound, agent and method to control pests |
| CN105120866B (en) | 2013-01-23 | 2020-02-14 | 奥尔德拉医疗公司 | Diseases and treatments associated with toxic aldehydes |
| JP6266023B2 (en) | 2013-01-25 | 2018-01-24 | アルデイラ セラピューティクス， インコーポレイテッド | A new trap in the treatment of macular degeneration |
| EP3178810A4 (en) * | 2014-08-08 | 2018-07-04 | Kasuma Partners Inc. | Condensed heterocyclic compound |
| EP3189026B1 (en) | 2014-09-02 | 2020-07-22 | The Regents of The University of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
| CN104926745A (en) * | 2015-07-14 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | Compounds containing benzisoxazole and terminal halogenation benzyl structures and application thereof |
| CN104974103A (en) * | 2015-07-14 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | Compound containing benzisoxazole and alcoxylphenyl structure and application thereof |
| WO2017035077A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| CA3022665A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| CN110431130A (en) | 2017-03-16 | 2019-11-08 | 奥尔德拉医疗公司 | Polymorphic compounds and their uses |
| CN111356451A (en) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | Treatment of Inflammatory Conditions |
| CN108586374B (en) * | 2018-01-12 | 2021-01-05 | 浙江鼎龙科技有限公司 | Preparation method of 2-phenylbenzoxazole compound |
| US12006298B2 (en) | 2018-08-06 | 2024-06-11 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN111467341B (en) * | 2020-04-24 | 2021-05-11 | 山东师范大学 | Application of 3,4-dimethoxyphenyl-benzo[d]oxazole as a tumor resistance reversal agent |
| EP4149470A4 (en) | 2020-05-13 | 2024-04-24 | Aldeyra Therapeutics, Inc. | PHARMACEUTICAL FORMULATIONS AND USES THEREOF |
| CN114805112A (en) * | 2022-05-31 | 2022-07-29 | 常州大学 | PDE2 inhibitor amide derivative and preparation method thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1435721A (en) | 1972-05-18 | 1976-05-12 | Lilly Industries Ltd | Benzoxazole derivatives |
| GB1590587A (en) | 1977-06-28 | 1981-06-03 | Lilly Industries Ltd | Benoxaprofen |
| PE27997A1 (en) * | 1994-04-29 | 1997-09-20 | Lilly Co Eli | TACHYCIN RECIPIENT ANTAGONISTS |
| DE792292T1 (en) | 1995-09-08 | 1998-09-03 | Karo Bio Ab, Huddinge | ORPHAN RECEPTOR |
| US5919808A (en) | 1996-10-23 | 1999-07-06 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| WO1998017267A1 (en) | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| US5948776A (en) | 1996-10-23 | 1999-09-07 | Zymogenetic, Inc. | Compositions and methods for treating bone deficit conditions |
| US7157568B1 (en) | 1997-08-05 | 2007-01-02 | American Home Products Corporation | Human estrogen receptor-β |
| EE04641B1 (en) | 1998-05-05 | 2006-06-15 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzimidazoles and benzoxazoles, their use in the manufacture of medicaments for the treatment of respiratory and dermatoses, and medicaments containing them |
| ES2219031T3 (en) | 1998-07-06 | 2004-11-16 | Altana Pharma Ag | NEW BENZOXAZOLES WITH PDE INHIBITING ACTIVITY. |
| GB9814620D0 (en) | 1998-07-06 | 1998-09-02 | Karobio Ab | Vasculoprotector |
| AU1199600A (en) | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
| EP1131336B1 (en) | 1998-11-20 | 2002-08-28 | Akzo Nobel N.V. | Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11 |
| AU765159B2 (en) | 1998-12-30 | 2003-09-11 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6331562B1 (en) | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6358943B1 (en) * | 1999-03-04 | 2002-03-19 | American Home Products Corporation | N-substituted indolines as estrogenic agents |
| CA2367895A1 (en) * | 1999-03-17 | 2000-09-21 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| AU3964400A (en) | 1999-04-06 | 2000-10-23 | Akzo Nobel N.V. | Selective estrogenic compounds |
| PT1165184E (en) | 1999-04-09 | 2004-04-30 | Karobio Ab | ANTAGONISM OF ESTROGEN'S RECEPTOR-BETA AND BONES DISEASES |
| TR200201762T2 (en) | 1999-04-16 | 2002-10-21 | Astrazeneca Ab | B estrogen receptor ligands. |
| US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
| GB9913649D0 (en) | 1999-06-11 | 1999-08-11 | Karobio Ab | Estrogen receptor |
| US6380166B1 (en) * | 1999-09-13 | 2002-04-30 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols |
| EP1257264B1 (en) | 2000-02-14 | 2011-09-14 | Merck Sharp & Dohme Corp. | Estrogen receptor modulators |
| US20070004713A1 (en) * | 2000-12-07 | 2007-01-04 | Bernard Barlaam | Therapeutic benimidazole compounds |
| JP2004524289A (en) * | 2000-12-22 | 2004-08-12 | アストラゼネカ・アクチエボラーグ | Therapeutic compounds |
| US6559177B2 (en) | 2001-04-19 | 2003-05-06 | Wyeth | 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents |
| UA83620C2 (en) * | 2001-12-05 | 2008-08-11 | Уайт | Substituted benzoxazoles and analogues as estrogenic agents |
| JP2008510827A (en) * | 2004-08-26 | 2008-04-10 | ワイス | Prodrug-substituted benzoxazoles as estrogen agents |
-
2002
- 2002-03-12 UA UA20040705301A patent/UA83620C2/en unknown
- 2002-12-03 NZ NZ560878A patent/NZ560878A/en unknown
- 2002-12-03 JP JP2003551120A patent/JP4689960B2/en not_active Expired - Fee Related
- 2002-12-03 IL IL16225602A patent/IL162256A0/en unknown
- 2002-12-03 TW TW091135030A patent/TW200304822A/en unknown
- 2002-12-03 BR BR0214767-0A patent/BR0214767A/en not_active IP Right Cessation
- 2002-12-03 CN CNA2008101731403A patent/CN101423500A/en active Pending
- 2002-12-03 PL PL02370771A patent/PL370771A1/en unknown
- 2002-12-03 CA CA2467517A patent/CA2467517C/en not_active Expired - Fee Related
- 2002-12-03 CN CNB028278186A patent/CN100443477C/en not_active Expired - Fee Related
- 2002-12-03 HU HU0500010A patent/HUP0500010A2/en unknown
- 2002-12-03 EP EP07023848A patent/EP1982713A3/en not_active Withdrawn
- 2002-12-03 SG SG200603829-3A patent/SG165987A1/en unknown
- 2002-12-03 RU RU2004120283/04A patent/RU2330847C2/en active
- 2002-12-03 KR KR1020047008680A patent/KR20050044717A/en not_active Abandoned
- 2002-12-03 MX MXPA04005306A patent/MXPA04005306A/en active IP Right Grant
- 2002-12-03 EP EP02789980A patent/EP1451165A1/en not_active Withdrawn
- 2002-12-03 WO PCT/US2002/038513 patent/WO2003050095A1/en not_active Ceased
- 2002-12-03 AU AU2002353014A patent/AU2002353014A1/en not_active Abandoned
- 2002-12-04 AR ARP020104690A patent/AR037745A1/en unknown
- 2002-12-04 US US10/309,699 patent/US6794403B2/en not_active Expired - Fee Related
-
2004
- 2004-05-17 US US10/847,100 patent/US7148247B2/en not_active Expired - Fee Related
- 2004-06-01 CO CO04050963A patent/CO5580830A2/en not_active Application Discontinuation
- 2004-06-04 EC EC2004005133A patent/ECSP045133A/en unknown
- 2004-07-01 ZA ZA200405249A patent/ZA200405249B/en unknown
- 2004-07-02 NO NO20042811A patent/NO20042811L/en not_active Application Discontinuation
- 2004-08-19 US US10/921,409 patent/US7129258B2/en not_active Expired - Fee Related
-
2005
- 2005-04-04 IN IN272KO2005 patent/IN2005KO00272A/en unknown
-
2006
- 2006-12-11 US US11/636,947 patent/US7531564B2/en not_active Expired - Fee Related
-
2008
- 2008-02-26 RU RU2008107295/04A patent/RU2008107295A/en not_active Application Discontinuation
-
2009
- 2009-08-17 AU AU2009210357A patent/AU2009210357A1/en not_active Ceased
-
2010
- 2010-11-15 JP JP2010255175A patent/JP2011052010A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2005KO00272A (en) | ||
| PT915866E (en) | APPROPRIATE PROCESS FOR THE SYNTHESIS OF PROTEED ESTERS OF (S) -3,4-DIHYDROXYBUTYRIC ACID | |
| HU913626D0 (en) | Process for the production of new aryl and heteroaryl-ethylene derivatives | |
| BG103980A (en) | 4-phenylpiperidine compounds | |
| NZ504372A (en) | Process to produce N-[3-fluoro-4(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinones | |
| MX23884A (en) | XANTINA DERIVATIVES AND PROCEDURE FOR ITS PREPARATION. | |
| NZ505220A (en) | Arylpiperazines having activity at the serotonin 1A receptor, processes for their preparation and intermediates | |
| PT1064281E (en) | BENZO-HETEROCYCLIC DISTAMICINE DERIVATIVES PROCESS FOR THE PREPARATION AND THEIR USE AS ANTITUMATIC AGENTS | |
| CO4990933A1 (en) | INDAZOL TRICYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | |
| HUP9900680A2 (en) | Acyclic nucleoside derivatives, process for producing them, pharmaceutical compositions containing them and method for the treatment of viral infections | |
| MY118004A (en) | Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | |
| MY127317A (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| PT1303514E (en) | PROCESS FOR THE PREPARATION OF AZACICLOALCANOYLAMINOTIAZOLES | |
| PT1628968E (en) | 4-imidazolin-2-one compounds( | |
| HUP9900679A2 (en) | Benzimidazole derivatives as inhibitors of smooth muscle cell proliferation, process for producing them and pharmaceutical compositions containing them | |
| CY1107481T1 (en) | ANTIOELECTIVE alkylation of tricyclic compounds | |
| HUP9902040A2 (en) | Process for producing 4-phenyl-1,2,3,6-tetrahydro-pyridine derivatives and the intermediates employed | |
| GB9812211D0 (en) | Cinnamoyl distamycin analogous derivatives,process for their preparation,and their use as antitumor agents | |
| DE60307792D1 (en) | HYDROXYLATED INDIRUBINE DERIVATIVES | |
| ATE238300T1 (en) | (3,4-DIHYDRO-2H-BENZO(1,4)OXAZINYL-METHYL)-3-(1 - INDOL-3-YL)-ALKYLAMINES | |
| DOP2001000226A (en) | PROCESS FOR PREPARING 2- (4-PIRIDIL) AMINO-6-DIALQUI- LOXIFENIL-PIRIDO [2,3-D] PIRIMIDIN-7-ONAS (PROCESS FOR PREPARING 2- (4-PYRIDIL) AMINO-6-DIALKYPHENYL-PYRIDO 2 , 3-D] | |
| ES8604591A1 (en) | PROCEDURE FOR PREPARING NEW 11-PIPERAZINYL-5H-IMIDAZO (2,1-C) (1,4) -BENZODIAZEPINES | |
| BRPI0516549A (en) | [2- (8,9-dioxo-2,6-diazabicyclo [5.2.0] non-1 (7) -en-2-yl) alkyl] phosphonic acid derivatives and methods for their manufacture | |
| NZ506912A (en) | Fungicidal 6-(2-halo-4-alkoxyphenyl)- triazolopyrimidines | |
| HUP9800889A1 (en) | New naphtylpiperazine derivatives |